( PASADENA Calif.--(BUSINESS WIRE)--Apr ...)Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect,with Lead RNAi Candidate,Health

PASADENA, Calif.--(BUSINESS WIRE)--Apr 3, 2007 - Calando Pharmaceuticals, a leading siRNA therapeutics company and a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ:ARWR) announced the publication of a study demonstrating the anti-proliferative effect of the siRNA sequence selected as the therapeutic component of its lead anti-cancer compound, CALAA-01.

The paper, entitled "Potent siRNA Inhibitors of Ribonucleotide Reductase Subunit RRM2 Reduce Cell Proliferation In vitro and In vivo," was published in the April 1 edition of Clinical Cancer Research, a journal published by the American Association of Cancer Research (AACR). This paper describes how Calando researchers and their collaborators determined the sequence of siRNA included in Calando's lead siRNA-containing nanoparticle formulation (CALAA-01). Numerous putative candidate siRNA duplexes targeting the M2 subunit of ribonucleotide reductase (RRM2) were screened, and those with maximal anti-RRM2 activity were further tested. The best candidate siRNA duplex demonstrated potent reduction of RRM2 protein levels in cultured cells and achieved a concomitant anti-proliferative effect in cells of multiple species (including human, mouse, rat, and monkey) and cancer types, both in vitro and in vivo. These findings confirm that this duplex is a promising candidate for therapeutic development.

"This paper highlights the results from screening experiments in which the sequence of Calando's lead anti-RRM2 siRNA was determined," said Jeremy Heidel, Calando's Chief Scientific Officer. "This duplex is powerful in its ability to down-regulate its target and elicits a strong anti-proliferative effect in a variety of types of cancer cells."

"These studies demonstrate the potential for this siRNA duplex to have a strong anti-tumor effect," said John Petrovich, Calando's Chief Executive Officer. Petrovich also noted that Calando has filed fo
'"/>

Page: 1 2 3 4
Related medicine technology :

1. Calando Pharmaceuticals Announces Preclinical Efficacy and Safety Data of Targeted, Systemic Delivery of siRNA at AACR Annual Meeting
2. Arrowhead Subsidiaries Insert & Calando Present Data on Cyclosert Drug Delivery System at AACR Meeting
3. Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate
4. Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on Targeted, Systemic Delivery of siRNA
5. Calando Pharmaceuticals Publishes the First Non-Human Primate Study on Targeted, Systemic Delivery of siRNA in National Academy of Sciences Journal
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
10. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
11. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference